THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM

被引：1
|
作者：
Schroeder, M. [1 ]
Johansen, P. [2 ]
Thompson, G. [1 ]
Willis, M. [3 ]
Neslusan, C. [4 ]
机构：
[1] Hanssen Ciiag UK, High Wycombe, Bucks, England
[2] Swedish Inst Hlth Econ IHE, Lund, Sweden
[3] Swedish Inst Hlth Econ, Lund, Sweden
[4] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.694
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB71
引用
收藏
页码：A344 / A344
页数：1
相关论文
共 50 条
  • [31] Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy
    Fulcher, Greg
    Matthews, David
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    DIABETES, 2013, 62 : A292 - A292
  • [32] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Davies, Michael
    Trujillo, Angelina
    Vijapurkar, Ujjwala
    Damara-Ju, C. V.
    Meininger, Gary
    DIABETES, 2014, 63 : A283 - A284
  • [33] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
    Gavin, James R., III
    Davies, Melanie J.
    Davies, Michael
    Vija-Purkar, Ujjwala
    Alba, Maria
    DIABETES, 2014, 63 : A285 - A285
  • [34] Efficacy of canagliflozin (CANA) in combination with metformin (MET) in patients with T2DM: Results from 3 studies
    Qiu, Rong
    Xie, John
    Hamilton, Gill
    Canovatchel, William
    Fegade, Mayuresh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S118 - S118
  • [35] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nicolle, Lindsay E.
    Capuano, George
    Fung, Albert
    Usiskin, Keith
    DIABETES, 2013, 62 : A296 - A296
  • [36] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS AN AD-ON TO METFORMIN OR METFORMIN PLUS SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
    Nielsen, A. T.
    Pitcher, A.
    Lovato, E.
    Schubert, A.
    Hemels, M.
    Neslusan, C.
    Gonzalez, B.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [37] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Weir, Matthew R.
    Januszewicz, Andrzej
    Gilbert, Richard
    Gonzalez, Fernando Lavalle
    Meininger, Gary
    DIABETES, 2013, 62 : A278 - A278
  • [38] Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
    Cheryl Neslusan
    Anna Teschemaker
    Michael Willis
    Pierre Johansen
    Lien Vo
    Diabetes Therapy, 2018, 9 : 565 - 581
  • [39] Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
    Neslusan, Cheryl
    Teschemaker, Anna
    Willis, Michael
    Johansen, Pierre
    Vo, Lien
    DIABETES THERAPY, 2018, 9 (02) : 565 - 581
  • [40] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS A DPP-4 INHIBITOR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
12345